Alpha 2.0
Login Register
» Journals » BMC Cancer

Bmc Cancer

BMC Cancer is an open-access, peer-reviewed journal that focuses on all aspects of cancer research, including prevention, diagnosis, treatment, and survivorship. It publishes high-quality articles that contribute to the understanding of cancer biology, genetics, epidemiology, and clinical trials. With a multidisciplinary approach, BMC Cancer aims to advance knowledge and promote collaboration in the fight against cancer.
Details
Abbr. BMC Cancer
Publisher Biomed Central
Start 2001
End Continuing
e-ISSN 1471-2407
Country United Kingdom
Language English
Specialty Oncology
Metrics
h-index / Ranks: 1242 160
SJR / Ranks: 3290 1087
CiteScore / Ranks: 3060 6.80
JIF / Ranks: 2461 3.8
Recent Articles
11.
Comparative inpatient care of cancer vs. non-cancer patients in Switzerland during the national COVID-19 lockdown: a nationwide interrupted time series analysis
Brunner L, Nicolet A, Peytremann-Bridevaux I, Marti J, Bulliard J, Righi L, et al.
BMC Cancer . 2025 Mar; 25(1):477. PMID: 40087645
Background: The COVID-19 pandemic exerted unprecedented pressure on healthcare systems worldwide, leading governments and hospitals to postpone elective procedures to prioritize care for COVID-19 patients. Cancer patients, who often require...
12.
Gender-specific differences in factors influencing supportive care needs in colorectal cancer patients
Zhang J, Dong B, Dong H, Guo D, Yuan Y, Tian L
BMC Cancer . 2025 Mar; 25(1):471. PMID: 40087644
Background: Unmet supportive care needs reducing the quality of life of colorectal cancer (CRC) patients. As existing studies have indicated the supportive care needs of CRC patients of different genders...
13.
A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate
Choate K, Konickson W, Moreno Z, Brill O, Cromell B, Detienne B, et al.
BMC Cancer . 2025 Mar; 25(1):473. PMID: 40087637
D-2-hydroxyglutarate (D-2-HG) is an oncometabolite that accumulates due to mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2). D-2-HG may be used as a surrogate marker for IDH1/2 mutant cancers, yet...
14.
Establishment and characterization of CHC-X1: the third human combined hepatocellular-cholangiocarcinoma cell line
Tang H, Chai C, Miao X, Su Y, Yu C, Yi J, et al.
BMC Cancer . 2025 Mar; 25(1):472. PMID: 40087624
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) represents an uncommon variant of primary liver cancer. In recent years, its incidence rate has increased. Thus, it is essential to perform comprehensive investigations into cHCC-CCA to...
15.
Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer
Zhao K, Lu S, Niu J, Zhu H, Tian Y, Yu J
BMC Cancer . 2025 Mar; 25(1):467. PMID: 40087602
Background: Immunotherapy combined with chemotherapy has shown good results in the treatment of extensive-stage small cell lung cancer (ES-SCLC), but there are fewer clinical studies on elderly ES-SCLC patients. This...
16.
Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma
Yin Z, Zhang H, Zhang K, Yue J, Tang R, Wang Y, et al.
BMC Cancer . 2025 Mar; 25(1):474. PMID: 40087599
Background: The combination of radiation with immune checkpoint inhibitors (ICIs) has been demonstrated to display synergistic effects in solid cancers. Nevertheless, the anti-tumor effect of combining radiation with programmed cell...
17.
Retraction Note: β2AR-HIF-1α-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells
Huang Z, Li G, Zhang Z, Gu R, Wang W, Lai X, et al.
BMC Cancer . 2025 Mar; 25(1):475. PMID: 40087587
No abstract available.
18.
Exploring FAM13A-N-Myc interactions to uncover potential targets in MYCN-amplified neuroblastoma: a study of protein interactions and molecular dynamics simulations
Yin H, Liu T, Wu D, Li X, Li G, Song W, et al.
BMC Cancer . 2025 Mar; 25(1):470. PMID: 40087586
Neuroblastoma (NB), a common infantile neuroendocrine tumor, presents a substantial therapeutic challenge when MYCN is amplified. Given that the protein structure of N-Myc is disordered, we utilized Alphafold for prediction...
19.
Effect of Helicobacter pylori infection on survival outcomes of patients undergoing radical gastrectomy after neoadjuvant chemotherapy: a multicenter study in China
He Q, Huang Z, Lv C, Wu Y, Qiu W, Ma Y, et al.
BMC Cancer . 2025 Mar; 25(1):460. PMID: 40082850
Background: Neoadjuvant chemotherapy (NAC) has been confirmed to improve the prognosis of patients with advanced gastric cancer (AGC). However, no study has investigated whether Helicobacter pylori (HP) infection affects the...
20.
Implementation and evaluation of a multi-professional care pathway and network for the promotion of needs-oriented, resident-oriented exercise therapy for oncological patients (MOVE-ONKO): protocol of a mixed-methods cohort study
Blutgen S, Krug K, Graf K, Betz U, Bohm J, Jager E, et al.
BMC Cancer . 2025 Mar; 25(1):458. PMID: 40082847
Background: Physical activity has been shown to be beneficial for people diagnosed with cancer. MOVE-ONKO aims at implementing a new multiprofessional care pathway in 3 large regions in Germany at...